Emergent Biosolutions Stock Today
| EBS Stock | USD 5.61 0.12 2.09% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Emergent Biosolutions is selling for under 5.61 as of the 21st of March 2025; that is 2.09 percent decrease since the beginning of the trading day. The stock's lowest day price was 5.61. Emergent Biosolutions has about a 39 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on January 13, 2025, Representative Steve Cohen of US Congress acquired under $15k worth of Emergent Biosolutions's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of November 2006 | Category Healthcare | Classification Health Care |
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. The company has 54.18 M outstanding shares of which 6.95 M shares are currently shorted by investors with about 5.21 days to cover. More on Emergent Biosolutions
Moving together with Emergent Stock
| 0.74 | IPA | Immunoprecise Antibodies | PairCorr |
| 0.75 | VOR | Vor Biopharma | PairCorr |
| 0.61 | MOLN | Molecular Partners | PairCorr |
Moving against Emergent Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Emergent Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Joseph Papa | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, Austrian Traded Index, HNX, ATX Prime, HNX MidSmall Cap, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEmergent Biosolutions can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Emergent Biosolutions' financial leverage. It provides some insight into what part of Emergent Biosolutions' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Emergent Biosolutions (EBS) is traded on New York Stock Exchange in USA. It is located in 400 Professional Drive, Gaithersburg, MD, United States, 20879 and employs 900 people. Emergent Biosolutions is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 540.22 M. Emergent Biosolutions runs under Biotechnology sector within Health Care industry. The entity has 54.18 M outstanding shares of which 6.95 M shares are currently shorted by investors with about 5.21 days to cover.
Emergent Biosolutions has about 642.6 M in cash with 58.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.28, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Emergent Biosolutions Probability Of Bankruptcy
Ownership AllocationEmergent Biosolutions holds a total of 54.18 Million outstanding shares. Over half of Emergent Biosolutions' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that on January 13, 2025, Representative Steve Cohen of US Congress acquired under $15k worth of Emergent Biosolutions's common stock.
Check Emergent Ownership Details
Emergent Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2024-12-31 | 969.1 K | |
| Palisade Capital Management Llc | 2024-12-31 | 938.7 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 920.8 K | |
| Connor Clark & Lunn Inv Mgmt Ltd | 2024-12-31 | 902.3 K | |
| Two Sigma Investments Llc | 2024-12-31 | 846.8 K | |
| Qube Research & Technologies | 2024-12-31 | 815.8 K | |
| Assenagon Asset Management Sa | 2024-12-31 | 766.5 K | |
| Trexquant Investment Lp | 2024-12-31 | 701.5 K | |
| Renaissance Technologies Corp | 2024-12-31 | 665.8 K | |
| Vanguard Group Inc | 2024-12-31 | 3.2 M | |
| American Century Companies Inc | 2024-12-31 | 2.1 M |
Emergent Biosolutions Historical Income Statement
Emergent Stock Against Markets
Emergent Biosolutions Corporate Directors
| Sue Bailey | Independent Director | Profile | |
| Jerome Hauer | Independent Director | Profile | |
| Kathryn Zoon | Independent Director | Profile | |
| Seamus Mulligan | Director | Profile |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.